Treatment of advanced prostatic carcinoma with a slow release depot LHRH analogue (Zoladex depot).
We treated 38 patients with newly diagnosed advanced prostatic cancer with monthly injections of a long acting depot preparation of a luteinizing hormone-releasing hormone superagonist (Zoladex depot). After 6 months' treatment 10% of the patients had complete objective regression, 77% had partial objective regression, 3% stable disease and 10% had objective progression. The LHRH analogue does not have the metabolic side effects of oestrogens. Depot luteinizing hormone-releasing hormone analogue may well become a preferred alternative for patients with advanced prostatic cancer.
Lukkarinen
O
O
Department of Surgery, Oulu University Central Hospital, Finland.
Kontturi
M
M
D000368:Aged; D000369:Aged, 80 and over; D002064:Buserelin / Q000031:analogs & derivatives* / Q000627:therapeutic use; D003692:Delayed-Action Preparations; D004334:Drug Administration Schedule; D004958:Estradiol / Q000031:analogs & derivatives / Q000627:therapeutic use; D045166:Estradiol Congeners / Q000627:therapeutic use; D017273:Goserelin; D006801:Humans; D007986:Luteinizing Hormone / Q000097:blood; D008297:Male; D008875:Middle Aged; D011471:Prostatic Neoplasms / Q000188:drug therapy*; D013739:Testosterone / Q000097:blood; D013997:Time Factors
D003692:Delayed-Action Preparations; D045166:Estradiol Congeners; D017273:Goserelin; D013739:Testosterone; D004958:Estradiol; D007986:Luteinizing Hormone; C008958:polyestradiol phosphate; D002064:Buserelin